Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Speculations Spark-off: Is A Deal Cooking Between Pfizer And India's Dr. Reddy's Labs?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Repeated denials of an imminent sell-off by India's Dr. Reddy's Labs failed to subdue a fresh round of speculations that linked Pfizer, a company said to be interested in buying out the domestic formulations business from the Hyderabad-headquartered company. Pfizer did not wish to comment and Dr. Reddy's strongly denied any plans to sell

You may also be interested in...



Dr. Reddy's CEO Dodges GSK Equity Deal Rumors - PharmAsia Summit

SAN FRANCISCO - Emotions should not come in the way of promoters wanting to sell their businesses, said Dr. Reddy's Labs Vice Chairman G.V. Prasad, while eluding questions pointed at a widely speculated equity deal between his company and GlaxoSmithKline

GSK In Pact With India’s Dr Reddy’s; Digs Deeper Into Emerging Generic Drugs Market

MUMBAI - Expanding its reach further into emerging markets for generic drugs, GlaxoSmithKline said it has reached an agreement with Dr. Reddy's Labs to develop and market select products across an extensive number of countries, except India

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC074128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel